All News

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

In total, 28% of patients with luminal tumors and 41% of patients with nonluminal tumors experienced upstaging to nonorgan confined disease.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

The primary end point is 12-month radiographic progression-free survival.

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

The data also showed that mortality plateaued in recent years despite declining in years prior.

"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors.

Overall, 403 medical students and other applicants were matched across 148 urology residency programs nationwide.

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

"What we show in our research is that cancers develop in different ways, depending on what the underlying genetic change is," says Taryn Treger.

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

"The biggest thing that I took away from using the device is that it allowed me to do the procedure by myself, without an assistant," says Matthew J. Mutter, MD.

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

Check out the key regulatory decisions set to happen early this year.

"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along with the nephrolithotomy codes (50080/50081) when both are performed at the same time by the same provider," write Jonathan Rubenstein, MD, and Mark Painter.

According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.

If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

At 25 weeks, FACT-P total score remained comparable between the arms.

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

The accuracy of PLND was 93.41% in the ICG injection arm compared with 75.91% in the control arm.

The median time to correct treatment was 98 days with initial TURBT compared with 53 days with initial mpMRI.